NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179)
NorthSea Therapeutics to Present ICONA Phase 2b Data
NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease
AMSTERDAM--(BUSINESS WIRE)--NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today provides an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic disorders.
AMSTERDAM--(BUSINESS WIRE)--NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces it has initiated a Phase 1 study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD.
The biotech announced the raise early this morning, which was co-led by Ysios Capital and Forbion Growth, and joined by new investor Hercules Capital. Some of the existing investors that hopped onto the round included Novo Seeds and Sofinnova, according to NorthSea.
NAARDEN, The Netherlands,--(BUSINESS WIRE)--NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces the presentation of new interim data from the Phase 2b ICONA trial during The Liver Meeting Digital Experience™ 2021 (TLMdX) of the American Association for the Study of Liver Diseases (AASLD), which was held online from November 12-15.